Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

BMC Health Serv Res. 2019 Dec 18;19(1):972. doi: 10.1186/s12913-019-4829-z.


In the original publication of this article [1], there is a mistake in the Fig. 2a, 2b, and 2c.

Publication types

  • Published Erratum